Mon panier

Biotinylated Human LIV-1 / SLC39A6 Protein, Fc,Avitag™ (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
LV1-H82F5-25ug
$360.00
LV1-H82F5-200ug
$1565.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    SLC39A6, LIV-1, ZIP6, Zinc transporter ZIP6, ZIP-6

  • Source

    Biotinylated Human LIV-1 Protein, Fc,Avitag (LV1-H82F5) is expressed from human 293 cells (HEK293). It contains AA Phe 29 - Trp 325 (Accession # Q13433-1).

    Request for sequence
  • Molecular Characterization

    LIV-1 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 61.8 kDa. The protein migrates as 80-95 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Purity

    >90% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 100 mM Glycine, 25 mM Arginine, 150 mM Nacl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    LIV-1 SDS-PAGE

    Biotinylated Human LIV-1 Protein, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    LIV-1 SEC-MALS

    The purity of Biotinylated Human LIV-1 Protein, Fc,Avitag (Cat. No. LV1-H82F5) is more than 90% and the molecular weight of this protein is around 160-190 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     LIV-1 ELISA

    Immobilized Anti-LIV-1 Antibody, Human IgG1 at 1 μg/mL (100 μL/well) can bind Biotinylated Human LIV-1 Protein, Fc,Avitag (Cat. No. LV1-H82F5) with a linear range of 0.1-4 ng/mL (QC tested).

    Protocol
  •  LIV-1 ELISA

    Immobilized Biotinylated Human LIV-1 Protein, Fc,Avitag (Cat. No. LV1-H82F5) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-LIV-1 Antibody, Human IgG1 with a linear range of 0.1-8 ng/mL (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

LIV-1 is also known as SLC39A6, ZIP-6 and Zinc transporter ZIP6. May act as a zinc-influx transporter. Highly expressed in the breast, prostate, placenta, kidney, pituitary and corpus callosum. Weakly expressed in heart and intestine. Also highly expressed in cells derived from an adenocarcinoma of the cervix and lung carcinoma. Up-regulated by estrogen in breast cancer cells lines.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Zinc transporter ZIP6

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    2 Détails

  • Étape de développement la plus élevée:

    Phase 2 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte